Inhibitors of transcription of fungal glucan synthase

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$100,000.00
Award Year:
2003
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI053954-01A1
Award Id:
65947
Agency Tracking Number:
AI053954
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
MYCOLOGICS, INC., 12635 E MONTVIEW BLVD, STE 131, AURORA, CO, 80010
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
CLAUDE SELITRENNIKOFF
(720) 859-4190
SELITRENNIKOFF@UCHSC.EDU
Business Contact:
CLAUDE SELITRENNIKOFF
(720) 859-4190
CLAUDE.SELITRENNIKOFF@UCHSC.EDU
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Perhaps the most striking difference between fungal cells and human cells is that fungal cells are encased in a wall that protects them from an osmotically and immunologically hostile external environment. In addition, the fungal cell wall relays signals for invasion and infection of a likely plant, animal, or human host. The cell wall is not an inert outer layer, but rather plays a dynamic role in all aspects of fungal physiology, e.g., morphogenesis, metabolite transport, protein secretion, intracellular signaling, and cell-cell contact. Cell-wall structure is now well characterized, at least in the ascomycetes, and appears to be very similar in human pathogens including Candida albicans, Penicillium spp., and Aspergillus spp. The fact that human cells lack a cell wall and the underlying biosynthetic and regulatory machinery to make the wall, suggests that drugs targeting cell-wall synthesis and assembly will be safe and specific antifungals. Current treatments for fungal infections are limited by few therapeutic options; these include amphotericin B, which interacts with membrane sterols, and a variety of azoles and allylamines that inhibit membrane sterol biosynthesis. Unfortunately, amphotericin B is toxic to humans and clinical resistance to azoles is increasing. These observations underscore the clear need for new antifungals. In this Phase I SBIR application, we propose to develop a novel screen that identifies inhibitors of transcription of a key gene for fungal cell-wall assembly, namely, the catalytic subunit of (1,3) beta-glucan synthase activity. This will be accomplished in two specific aims: Aim One: Development of a screen to identify inhibitors of transcription of the FKS gene encoding the catalytic subunit of (1,3) beta -glucan synthase. Aim Two: Screen 3,000 pure compounds for inhibitors of transcription of the (1,3) beta -glucan synthase FKS gene. Importantly, we will determine the effect of putative inhibitors on fungal growth, on human-cell toxicity, and on the levels of FKS message. This work will lead to a novel assay that will be used for the discovery of new antifungal compounds. In turn, these novel compounds will be developed for the treatment of human fungal diseases.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government